Drug Profile


Alternative Names: BW 301U; Piritrexim isethionate

Latest Information Update: 25 Mar 2003

Price : $50

At a glance

  • Originator ILEX Oncology Inc
  • Class Pyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Kaposi's sarcoma; Pain
  • Discontinued Bladder cancer

Most Recent Events

  • 25 Mar 2003 A study has been added to the Cancer therapeutic trials section
  • 13 Nov 1998 Discontinued-II for Bladder cancer in European Union (PO)
  • 13 Nov 1998 Discontinued-II for Bladder cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top